Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis. [PDF]
CureusObjectives Tofacitinib, an effective Janus kinase inhibitor (JAKi), has gained increasing interest in recent years for the management of refractory alopecia areata (AA). One of the most prevalent autoimmune diseases is AA, a kind of non-scarring alopecia.
Tirmizi SS +3 more
europepmc +6 more sources
Viral-Induced Rapidly Progressive Alopecia Universalis: A Case Report and Literature Review. [PDF]
Cureus, 2023 Alopecia areata is a common autoimmune condition that causes a non-scarring form of hair loss. It is associated with several viruses and diseases. One of the viruses that have been linked to alopecia areata is the coronavirus disease of 2019 (COVID-19 ...
Alotaibi MA +3 more
europepmc +4 more sources
A rare case of alopecia universalis. [PDF]
Pan Afr Med J, 2023 A 28-year-old patient came to the outpatient department of Mahatma Gandhi Ayurved College Hospital and Research Center, Salod, Wardha with complete loss of hairs from all over the body. First, he had Alopecia areata, but then he developed complete hair loss. He took various medications but of no use. Alopecia universalis is a rare variation of alopecia
Deshpande A, Deshpande M.
europepmc +5 more sources
Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report. [PDF]
CureusThis case report describes a 30-year-old male patient with extensively treatment-resistant alopecia universalis in the context of autoimmune and atopic comorbidities, including eczema, asthma, severe allergic reactions, and Hashimoto’s thyroiditis.
Bhardwaj S +4 more
europepmc +4 more sources
Treatment outcomes and considerations for topical immunotherapy in patients with alopecia totalis and alopecia universalis [PDF]
Front Med (Lausanne)Background Alopecia areata (AA) is a chronic immune-mediated disorder causing non-scarring hair loss. Severe forms like alopecia totalis (AT) and alopecia universalis (AU) pose therapeutic difficult situations.
Hitaka T +6 more
europepmc +4 more sources
Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor. [PDF]
J Inflamm Res, 2023 Drug-induced alopecia areata is a rare adverse event wherein medications such as antimicrobials, anticonvulsants, and biologics, trigger the premature transition of actively growing hairs into the telogen phase.
Teng Y, Fan Y, Shang D, Tao X, Sun D.
europepmc +4 more sources
Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population. [PDF]
JAMA Dermatol, 2023 Key Points Question What is the contemporary prevalence and incidence of alopecia areata (AA), alopecia totalis, and alopecia universalis in the US? Findings In this cohort study of a nationwide US employer-sponsored insurance population, AA prevalence ...
Mostaghimi A +7 more
europepmc +3 more sources
Tofacitinib in the Management of Alopecia Universalis.
Int J Trichology, 2023 ABSTRACT Alopecia universalis (AU) is a rare form of hair loss characterized by the complete absence of hair on the scalp and body. It is an advanced form of alopecia areata. There is currently no definitive treatment for this condition, and management options are limited.
Agarwal P.
europepmc +4 more sources
Myeloproliferative disorder associated with alopecia universalis. [PDF]
JAAD Case RepKarim MS, Karim HS, Rambhatla PV.
europepmc +5 more sources
Two pediatric cases of alopecia universalis with concomitant atopic dermatitis successfully treated with baricitinib [PDF]
JAAD Case RepShoichiro Muratani +2 more
europepmc +3 more sources